5 Biotech And Medical Device Stocks In Focus: Pro-Dex, Modular Medical, ENvue Medical & More

Pro-Dex (PDEX) reported strong fiscal 2026 results with 17% Q4 sales growth and 16% annual sales increase. Modular Medical (MODD) gained FDA clearance for Pivot pump software. ENvue Medical (FEED) selected for Vizient Innovative Technology Exchange. Attovia (ATTO) and Pyxis Oncology (PYXS) provided clinical updates and financials. All stocks rose Friday.

Original reporting
Published Sep 4, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PDEX
Bullish
high confidence
Mentioned
$PDEX · $MODD · $FEED · $ATTO · $PYXS
Relevance
6/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PDEXBullishMed
01

Why it matters

The mix of strong earnings and regulatory approvals provides short‑term bullish catalysts for several small‑cap stocks, while loss‑making firms remain dependent on upcoming trial data.

02

Market read

Earnings and FDA clearance drive immediate price moves; broader sector may see modest uplift.

03

What to watch

Potential regulatory delays for MODD's rollout and competitive pressure on ATTO and PYXS pipelines.

Relevance 6/10Novelty 7/10Timing: Friday after market close

Background

Mid‑week roundup of biotech and medical‑device companies highlighting earnings, regulatory milestones, and conference selections.

Company-level read

Ticker impact

$PDEXBullishHigh confidence
Context

Reported strong fiscal 2026 Q4 and full-year earnings, shares up 16% on the news.

Expected impact

Potential further upside as investors digest strong earnings.

Evidence & confidence

Revenue and net income rose double‑digits YoY, and the stock already jumped 16%.

$MODDBullishMedium confidence
Context

Announced FDA clearance for software enhancements to its Pivot insulin patch pump.

Expected impact

Likely modest upside as rollout begins in October.

Evidence & confidence

Clearance is a key milestone for a medical‑device firm.

$FEEDBullishMedium confidence
Context

Selected to exhibit its ENvue Navigation Platform at the Vizient Innovative Technology Exchange.

Expected impact

Potential incremental gain pending commercial traction.

Evidence & confidence

Conference selection signals market interest but no immediate revenue.

$ATTONeutralLow confidence
Context

Reported Q2 2026 net loss and announced a global Phase 2 trial for ATTO‑1310.

Expected impact

Limited short‑term move; watch trial data release.

Evidence & confidence

Financials are weak, but pipeline progress adds upside potential.

$PYXSNeutralLow confidence
Context

Reported Q2 2026 net loss and outlined upcoming Phase 1/2 data with KEYTRUDA.

Expected impact

Possible volatility around data releases later in 2026.

Evidence & confidence

Current financials are negative; future trial results are the main driver.

Market effects

Biotech earnings season may lift peer valuations; FDA clearance adds optimism for med‑device sector.

U.S. small‑cap biotech and med‑device stocks could see modest gains.

Limited to niche healthcare investors; no broad macro impact.

Counterpoint

High earnings multiples may be overvalued; price could correct if guidance falls short.

Key entities

  • Pro‑Dex Inc.

    Biotech firm reporting FY2026 earnings.

  • Modular Medical Inc.

    Medical‑device maker receiving FDA clearance.

  • ENvue Medical Inc.

    Selected for Vizient conference showcase.

  • Attovia Therapeutics Inc.

    Biotech reporting Q2 loss and Phase 2 plans.

  • Pyxis Oncology Inc.

    Oncology firm reporting Q2 loss and upcoming trial data.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$PYXSMed

Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO)

Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) Updated Phase 1 monotherapy results in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2